The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here to read why PCRX stock is a Buy.

Journavx costs $15.50 per 50 mg tablet, taken twice daily, making it pricier than opioids. Vertex's Q4 sales hit $2.91 billion, up 16% YoY, beating the $2.78 billion consensus. Learn how to trade ...

Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new pain medication Journavx in a less favorable Tier 3 coverage in two ...